p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy

Danila Coradini, Elia Biganzoli, Ilaria Ardoino, Federico Ambrogi, Patrizia Boracchi, Romano Demicheli, Maria Grazia Daidone, Angela Moliterni

Research output: Contribution to journalArticlepeer-review

Abstract

Genomic analysis and protein expression assimilate triple-negative breast cancers (TNBC) with basal-like breast tumors. TNBCs, however, have proved to encompass also tumors with normal-like phenotype and known to have favorable prognosis and to respond to chemotherapy. In a recent paper, we have provided evidence that p53 status is able to subdivide TNBCs into two distinct subgroups with different outcome, and consistent with basal- and normal-like phenotypes. Based on this finding, we explored the contribution of p53 status in predicting the response to adjuvant CMF or CMF followed doxorubicin chemotherapy of a group of TNBC patients. Results indicated that TNBC patients with a p53-positive tumor had a shorter relapse-free and overall survival than patients carrying a p53-negative TNBC, corroborating our hypothesis about the relationship between TNBC phenotype (basal-like versus normal-like) and p53 status as predictor of response to antracycline/CMF-based chemotherapy.

Original languageEnglish
Pages (from-to)294-297
Number of pages4
JournalBreast
Volume24
Issue number3
DOIs
Publication statusPublished - Jun 1 2015

Keywords

  • Adjuvant chemotherapy
  • Breast cancer
  • P53 status
  • Triple negative

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Fingerprint Dive into the research topics of 'p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy'. Together they form a unique fingerprint.

Cite this